Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Ling Ying Lu, Po Hao Feng, Ming Sun Yu, Min Chi Chen, Alex Jia Hong Lin, Justin L. Chen, Lennex Hsueh Lin Yu

研究成果: 雜誌貢獻簡短的問卷調查同行評審

1 引文 斯高帕斯(Scopus)

摘要

Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.
原文英語
頁(從 - 到)34-43
頁數10
期刊Cytokine and Growth Factor Reviews
63
DOIs
出版狀態已發佈 - 2月 2022

ASJC Scopus subject areas

  • 內分泌學、糖尿病和代謝
  • 免疫學和過敏
  • 免疫學
  • 生物化學、遺傳與分子生物學 (全部)

指紋

深入研究「Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review」主題。共同形成了獨特的指紋。

引用此